Furthermore, ATCs with CDKN2A loss displayed up-regulation of CD274 (PD-L1) and PDCD1LG2 (PD-L2), which are favorable immunotherapeutic targets for treating cancer37, in agreement with a previous report that showed the expression of PD-L1 in ATC40. This evidence concerns the gene CD274 and Ehlers-Danlos syndrome, musculocontractural type.